Cargando…

Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials

BACKGROUND: The majority of clinical trials of first-line systemic treatments for hepatocellular carcinoma (HCC) used placebo or sorafenib as comparators, and there are limited data providing a cross comparison of treatments in this setting, especially for newly-approved immune checkpoint inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Yue, Zhi, Wei-Hua, Xu, Fei, Zhang, Chen-Bo, Huang, Xiao-Qian, Luo, Jian-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Meta-Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130040/ https://www.ncbi.nlm.nih.gov/pubmed/34040331 http://dx.doi.org/10.3748/wjg.v27.i19.2415

Ejemplares similares

First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis
por: Fong, Khi Yung, et al.
Publicado: (2022)

Network meta-analysis of the efficacy of first-line chemotherapy regimens in patients with advanced colorectal cancer
por: Wu, Dong-Mei, et al.
Publicado: (2017)

First-line systemic therapy for advanced gastric cancer: a systematic review and network meta-analysis
por: Cheng, Ji, et al.
Publicado: (2019)

Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis
por: Ridouane, Yassine, et al.
Publicado: (2017)

First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis
por: Tao, Jiahao, et al.
Publicado: (2022)

Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis
por: Vogel, Arndt, et al.
Publicado: (2023)

The efficacy and safety of first-line therapies for preventing chronic post-surgical pain: a network meta-analysis
por: Ning, Jie, et al.
Publicado: (2017)

Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
por: Zhang, Zhonghan, et al.
Publicado: (2019)

The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials
por: Jang, Hyun Joo, et al.
Publicado: (2017)

The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysis
por: Kim, Bum Jun, et al.
Publicado: (2017)

Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma
por: Petersohn, Svenja, et al.
Publicado: (2023)

Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis
por: Wenfan, Fu, et al.
Publicado: (2023)

Comparative effectiveness of first-line therapies for eradication of antibiotic-resistant Helicobacter pylori strains: A network meta-analysis
por: Zou, Shu-Peng, et al.
Publicado: (2022)

Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Lu, Fei, et al.
Publicado: (2021)

Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Trials
por: Tan, Darren Jun Hao, et al.
Publicado: (2023)

Prognostic value of microRNAs in hepatocellular carcinoma: a meta-analysis
por: Zhang, Yue, et al.
Publicado: (2017)

Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis
por: Citterio, Chiara, et al.
Publicado: (2018)

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis
por: Cattrini, Carlo, et al.
Publicado: (2021)

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%
por: Freemantle, Nick, et al.
Publicado: (2022)

Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)

Systematic review and meta-analysis of third-line salvage therapy for the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials
por: Zhang, Nan, et al.
Publicado: (2018)

Hepatocellular carcinoma recurrence in living and deceased donor liver transplantation: a systematic review and meta-analysis
por: Zhang, Hai-Ming, et al.
Publicado: (2019)

Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis
por: Cao, Jing, et al.
Publicado: (2019)

First-line therapeutic strategy for patients with advanced non–small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis
por: Chen, Chongxiang, et al.
Publicado: (2022)

Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis
por: Wen, Yaokai, et al.
Publicado: (2022)

Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis
por: Chen, Hao, et al.
Publicado: (2020)

Rituximab Treatment Strategy for Patients with Diffuse Large B-Cell Lymphoma after First-Line Therapy: A Systematic Review and Meta-Analysis
por: Ren, Yuan-Rong, et al.
Publicado: (2015)

Photodynamic therapy for middle-advanced stage upper gastrointestinal carcinomas: A systematic review and meta-analysis
por: Chen, Bo, et al.
Publicado: (2018)

What is the best combination treatment with transarterial chemoembolization of unresectable hepatocellular carcinoma? a systematic review and network meta-analysis
por: Xie, Hui, et al.
Publicado: (2017)

Epigenetic basis of hepatocellular carcinoma: A network-based integrative meta-analysis
por: Bhat, Venkat, et al.
Publicado: (2018)

Prognostic and clinicopathological significance of PD-1 expression in hepatocellular carcinoma: a meta-analysis
por: Zhang, Qian, et al.
Publicado: (2020)

Dose age affect the efficacy of molecular targeted agents in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis
por: Du, Jing, et al.
Publicado: (2017)

Efficacy and safety of intraperitoneal chemotherapy in patients with advanced gastric cancer: a cumulative meta-analysis of randomized controlled trials
por: He, Zheng, et al.
Publicado: (2017)

Meta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer
por: Li, Fei, et al.
Publicado: (2017)

Assessment of prophylactic antibiotics administration for acute pancreatitis: a meta-analysis of randomized controlled trials
por: Ding, Nan, et al.
Publicado: (2020)

Repeat resection versus percutaneous ablation for recurrent hepatocellular carcinoma: a meta-analysis
por: Zhang, Feng-Qin, et al.
Publicado: (2022)

Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis
por: Cho, Yo-Han, et al.
Publicado: (2017)

Efficacy and safety of radiofrequency ablation for treatment of knee osteoarthritis: a meta-analysis of randomized controlled trials
por: Zhang, Hua, et al.
Publicado: (2021)

Transcatheter hepatic arterial chemoembolization and sorafenib for hepatocellular carcinoma: a meta-analysis of randomized, double-blind controlled trials
por: Li, Jun, et al.
Publicado: (2017)

Is FOLFOXIRI alone or combined with targeted therapy administered as first-line treatment a reasonable choice for most patients with mCRC? Systematic review and network meta-analysis
por: Zhou, Mingyi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_50n9f0a2himfqiu331bfk4pfgu